Table 2.

TLR4-targeting ligands currently in clinical trials.

Compound	Class	Disease Model	Activity	Phase	Identifier/Status
Eritoran	Glycolipid	Insulin sensitivity	Antagonist	II	NCT02321111/Completed 3
GLA-SE 1	Glycolipid	Stage III & IV soft tissue sarcoma	Agonist	I	NCT02180698/Completed
GLA (Mart-1 Antigen)	Glycolipid	Stage IIA, IIB, IIC, IIIA, IIIB, IIIC & IV melanoma	Agonist	I	NCT02320305/Active
GLA-SE	Glycolipid	Metastatic colorectal cancer	Agonist	I	NCT03982121/Active
GSK1795091	Glycolipid	Cancer, neoplasms	agonist	I	NCT02798978/Completed
NI-0101	Antibody	Rheumatoid arthritis	antagonist	II	NCT03241108/Completed
G100	Glycolipid	Follicular low-grade non-Hodgkin’s lymphoma	Agonist	I	NCT02501473/Active
CX-01	Polysaccharide	Myelodysplastic syndrome, AML 2	Antagonist	I	NCT02995655/Completed
GLA-SE	Glycolipid	Merkel cell carcinoma	Agonist	I	NCT02035657/Completed
G100	Glycolipid	Lymphoma	Agonist	II	NCT03742804/Not yet recruiting
GLA-SE	Glycolipid	Schistosomiasis	Agonist	II	NCT03041766/Completed
GLA	Glycolipid	Hookworm infection	Agonist	I	NCT01717950/Completed
JKB-121	Small molecule	Nonalcoholic steatohepatitis	Antagonist	II	NCT02442687/Completed
Ibudilast	Small molecule	Methamphetamine use disorder	Antagonist	II	NCT01860807/Completed

¹ GLA: glucopyranosyl lipid A; ² AML: acute myeloid leukemia; ³ NCT: national clinical trial.